A Unique Partnership to Advance Alzheimer's Research through Whole Genome Sequencing.
|
|
- Bartholomew James
- 5 years ago
- Views:
Transcription
1 A Unique Partnership to Advance Alzheimer's Research through Whole Genome Sequencing. Dean Hartley, Ph.D., Alzheimer's Association, Emily Drabant, Ph.D., 23 and me, Anne Wojcicki, 23 and me, Rob Fetherstonhaugh, The Brin Wojcicki Foundation, Heather Snyder, Ph.D., Alzheimer's Association, William Thies, Ph.D., Alzheimer's Association, and Maria Carrillo, Ph.D., Alzheimer's Association
2 A Unique Alliance Against Alzheimer s New Alliance: Alzheimer s Association, Alzheimer s Disease Neuroimaging Initiative, and Brin Wojcicki Foundation Objective: Conduct whole genome (DNA) sequencing on one of the most well characterized disease population: the ADNI Cohort studying Alzheimer s disease. Goal: To provide an unprecedented access to genetic information for identifying important associations between a person genetic profile and Alzheimer s disease.
3 Alzheimer s Disease A Global Crisis Over 5 million American s with Alzheimer s Worldwide nearly 36 million with Alzheimer's
4 Alzheimer s and Mortality 6 th leading cause of death Deaths from Alzheimer s increased 66% (between ) No treatments to slow or prevent Alzheimer s
5 A Unique Alliance for Rapid Discovery alzheimer s association the brin wojcicki foundation
6 Alzheimer s Association The Alzheimer s Association is the world s leading voluntary health organization in Alzheimer care, support and research. The mission of the Alzheimer s Association s is to: eliminate Alzheimer s disease through the advancement of research to provide and enhance care and support for all affected to reduce the risk of dementia through the promotion of brain health.
7 Brin Wojcicki Foundation The Brin Wojcicki Foundation was established by Sergey Brin and Anne Wojcicki. The Brin Wojcicki Foundation's mission is to: effect world change in Parkinson's research and neurodegenerative diseases to develop opportunities for those in need in poverty, health and education to support transformational and disruptive research
8 Alzheimer s Disease Neuroimaging Initiative A Unique Model of Open Access Michael Weiner, MD University of California, San Francisco Robert C. Green, MD, MPH Brigham and Women s Hospital, Harvard Medical School Neil Buckholtz, PhD National Institute on Aging (NIA)
9 ADNI - Private/Philanthropic/Public Partnership Industry partners (20) Philanthropic partners Foundation of the NIH National Institute on Aging Acquisitions Sites (59)
10 ADNI Participating Sites
11 Alzheimers Disease Neuroimaging Initiative (ADNI) ADNI is public-private partnership to increase our understanding of Alzheimer s disease ADNI is longitudinal study to evaluated the value of neuroimaging and other biomarkers to determine the onset and progression of Alzheimer s disease.
12 Neuroimaging RED = maximum uptake VIOLET = minimum uptake Clark et al. (2011) JAMA 305(1).
13 Alzheimer s Continuum & ADNI Normal EMCI MCI AD
14 DNA Encodes Proteins Down s Patients Have an Extra Copy of the Amyloid Precursor Protein
15 DNA is the Blue Print for Life Nature Biotechnology 30, (2012)
16 Cost per Human Genome Sequencing Costs are Dropping Reduction in the cost of DNA sequencing help to driving the project Costs will continue to drop over time, make this more assessable.
17 Whole Genome Sequencing The inspiration for this project is the ANDI data set The approach is applicable to most diseases.
18 MOU and Financial Costs The Brin Wojcicki Foundation will provide at least $1 million. The Alzheimer's Association will provide $1 million. Upon completion and certification by ADNI that the services have been performed satisfactorily and are completed. lllumina will be running the sequencing for the project.
19 Populations for Sequencing ADNI Participants Sent for Sequencing Population Number of Participants AD 128 MCI 415 Controls 267 Unstable 8 TOTAL 818
20 Information Flow Patients ADNI Alzheimer s Disease Neuroimaging Initiative (ADNI) DATA Hard Drives LONI/ ADNI Quality Control Data Repository Data Requests Data - No Charge National Cell Repository for Alzheimer's Disease (NCRAD) NCRAD DNA (ID) Illumina, Inc. Scientific Communities
21 Access to ADNI Data How to Apply for ADNI Data o Data Sharing and Publication Policy o Data Use Agreement o ADNI Manuscript Citations o Group Acknowledgements List
22 Progress Initial Discussions MOU DNA Sequencing Data Quality Control All Sequencing Data Released Further Development: Cloud Computing Distribution and Analytics Early 2012 June 2012 Dec 2012 Spring/Summer 2013
23 Potentially groundbreaking importance: The ability to match highly-robust cognitive, biochemical and neuroimaging data with newly-generated gene sequence data. The ability to mine for novel targets for risk assessment, new therapies, and much-needed insight into the causes of this devastating brain disease.
24 Potential of the Data Set The Data will help to identify a gene or multiple genes Increase risk Induce disease initiation Effect the progression of the disease Identify targets for therapy Possibly suggest individualized risks and treatments
25 Are we ready for Big Data?
26 Global Alzheimer s Association Interactive Network (GAAIN) - To Speed Sharing and Discoveries Program Development Committee: Maria Carrillo, Ph.D. - Alzheimer s Association Art Toga, Ph.D. UCLA, Laboratory of Neuro Imaging Giovanni Frisoni, M.D., Nat. Ctr. Alzheimer s Disease Research and Care, Italy.
27 Global Alzheimer s Association Interactive Network (GAAIN) - To Speed Discoveries GAAIN is a cloud-based computing data repository to share data available by the world s foremost Alzheimer s researchers. GAAIN will provide tools and access to data for scientists all over the world to explore a vast, interlinked network of both basic and clinical data. Collaborators: Rhett Alden, GE Healthcare Enrique Castro-Leon, Intel Alon Halevy, Google
28 Big Data How will we comprehend? 90% of digital data is < 2 years old 80% of the data in unstructured 800% increase in data over next 5 years Watson Ushering in a new era of computing
29 Summary A visionary partnership that saw an opportunity to: 1) move quickly to generate a unique data set for Alzheimer s Community 2) provide an opportunity to share important data worldwide 3) expedite the discovery process with the goal of changing the course of Alzheimer s disease. alzheimer s association the brin wojcicki foundation
Heather M. Snyder, Ph.D. Director, Medical & Scientific Relations
Heather M. Snyder, Ph.D. Director, Medical & Scientific Relations 1 Overview Landscape of Alzheimer s disease National Plan to Address Alzheimer s disease More information about the Alzheimer s Association
More informationWatson Summit Prague 2017
Watson for Oncology Matěj Adam Watson Health Executive May 2017 Watson Summit Prague 2017 an IBM Company Leadership & 23 Years Patent Leadership Research Spend Global Presence Technology 7300+ 2015 $6B
More informationADNI Experience on Developing Biomarker Tools as Example of An Approach to Catalyzing Dry AMD Drug Development
ADNI Experience on Developing Biomarker Tools as Example of An Approach to Catalyzing Dry AMD Drug Development Wm Z Potter, MD, PhD Sr. Advisor, NIMH IOM, Nov 15, 2014 Disclosures Former employee of Lilly
More informationRe: Request for Information: Updating the Alzheimer s Disease-Related Dementias Research Priorities
Public Policy Division 202.393.7737 p 1212 New York Ave NW 866.865.0270 f Suite 800 www.alz.org Washington, DC 20005 Roderick Corriveau, Ph.D. Program Director National Institute of Neurological Disorders
More informationBioArctic announces detailed results of the BAN2401 Phase 2b study in early Alzheimer s disease presented at AAIC 2018
Press release BioArctic announces detailed results of the BAN2401 Phase 2b study in early Alzheimer s disease presented at AAIC 2018 Stockholm, Sweden, July 25, 2018 BioArctic AB (publ) (Nasdaq Stockholm:
More informationFirst US Plan to Address Alzheimer s Disease
First US Plan to Address Alzheimer s Disease Advisory Council on Research, Care and Services for the National Alzheimer s Project Act 2012 MFMER 3205603-1 Passed by Congress 2010 December January 2011
More informationG8 Dementia Summit. Joint Opening Plenary
G8 Dementia Summit Joint Opening Plenary London, 11 December 2013 Speech by Yves Leterme Deputy Secretary-General, OECD 0 Secretary of State Jeremy Hunt, Director General of the World Health Organisation
More information10 Signs of AD. Sources for Information and Support. Inside this issue: National Centralized Repository. Alzheimer s Disease and Related Dementias
Sources for Information and Support Alzheimer s Association http://www.alz.org Tel: 312-335-8700 or 800-272-3900 National Parkinson Foundation http://www.parkinson.org/ Tel: 305-547-6666 or 800-327-4545
More informationBackground. In discussions of recruitment, the question was raised as to whether returning research results to subjects would help recruitment.
Alzheimer s Disease Neuroimaging Initiative Return of Research Results Working Group The REVEAL Study NHGRI/NIA Funded d 2000-2013 2013 Background In discussions of recruitment, the question was raised
More informationFirst US Plan to Address Alzheimer s Disease
First US Plan to Address Alzheimer s Disease Ronald C. Petersen, PhD, MD Chair Advisory Council on Research, Care and Services for the National Alzheimer s Project Act 2012 MFMER 3205603-1 NAPA Advisory
More informationAlzheimer s disease. The future of clinical trials: big problem, Big Data, big solution?
Alzheimer s disease The future of clinical trials: big problem, Big Data, big solution? The Problem More than 36m people with dementia Consumes 1% global GDP Serial trials failure Targets for therapy Nothing
More informationNational Academies Next Generation SAMPLE Researchers TITLE Initiative HERE
National Academies Next Generation SAMPLE Researchers TITLE Initiative HERE Dennis A. Dean, II, PhD Sanofi Auditorium July 13, 2017 sevenbridges.com A little about me Research Experience Analytics and
More informationThe G8 Dementia Summit: A Giant Step Forward for Dementia
The G8 Dementia Summit: A Giant Step Forward for Dementia January 28, 2014 Mimi Lowi-Young, M.H.A, Dip Bus. Admin., FACHE, FCCHL Chief Executive Officer, Alzheimer Society of Canada Overview 1. Background
More informationTranslational Cardiac Stem Cell Program ( TCSCP )
Translational Cardiac Stem Cell Program ( TCSCP ) 2017 Developing Revolutionary Treatments for Multiple Diseases Dr. Yerem founded the TCSCP in 2003 to develop revolutionary treatments for life threatening
More informationMelanoma Research Alliance-Pfizer Academic-Industry Partnership Awards
Melanoma Research Alliance-Pfizer Academic-Industry Partnership Awards Wendy K.D. Selig, President & CEO, MRA Julia Perkins, M.D. Medical Director, Oncology, Pfizer Melanoma Research Alliance Mission:
More informationDefeating dementia: progress and challenges on the road to 2025
Defeating dementia: progress and challenges on the road to 2025 Data sharing panel Moderator: Dr Steven Hyman Harvard University Distinguished Professor and Director, Stanley Center at the Broad Institute
More informationClaims & Underwriting. You already told us that story! Maria C. Carrillo, Ph.D. Sr. Director, Medical & Scientific Relations Alzheimer s Association
Claims & Underwriting Alzheimer s & Cognitive Impairment: You already told us that story! Maria C. Carrillo, Ph.D. Sr. Director, Medical & Scientific Relations Alzheimer s Association 1 OVERVIEW Impact
More informationAlzheimer s Disease. Fact Sheet. Fact Sheet. Fact Sheet. What Causes AD?
2 Alzheimer s Disease Dementia is a brain disorder that seriously affects a person s ability to carry out daily activities. The most common form of dementia among older people is Alzheimer s disease (AD),
More informationBig Data Phenomics in the VA. Outline
Big Phenomics in the VA Mary Whooley MD Director, VA Measurement Science QUERI San Francisco VA Health Care System University of California, San Francisco Kelly Cho PhD MPH Phenomics Lead, Million Veteran
More informationIndiana University School of Medicine, Indianapolis, IN USA 1
GWAS and Candidate Studies of MRI and Amyloid PET Phenotypes for Alzheimer's Disease Andrew J. Saykin Depts. of Radiology & Imaging Sciences and Medical & Molecular Genetics, Neurology & Psychiatry; Indiana
More informationBioArctic announces positive topline results of BAN2401 Phase 2b at 18 months in early Alzheimer s Disease
Press release BioArctic announces positive topline results of BAN2401 Phase 2b at 18 months in early Alzheimer s Disease The full 18 month analysis of the 856 patient BAN2401 Phase 2b clinical study in
More informationI, Mary M. Langman, Director, Information Issues and Policy, Medical Library Association
I, Mary M. Langman, Director, Information Issues and Policy, Medical Library Association (MLA), submit this statement on behalf of MLA and the Association of Academic Health Sciences Libraries (AAHSL).
More informationAlzheimer s Association: Public Health Perspectives & Initiatives
Alzheimer s Association: Public Health Perspectives & Initiatives Maria C. Carrillo, Ph.D. Chief Science Officer Disclosures: Full time employee of the Alzheimer s Association 2 Outline Prevalence vs Incidence
More informationRequest for Applications Post-Traumatic Stress Disorder GWAS
Request for Applications Post-Traumatic Stress Disorder GWAS PROGRAM OVERVIEW Cohen Veterans Bioscience & The Stanley Center for Psychiatric Research at the Broad Institute Collaboration are supporting
More informationCREATION OF A TORONTO CENTRE FOR DEMENTIA RESEARCH
CREATION OF A TORONTO CENTRE FOR DEMENTIA RESEARCH Barry D. Greenberg, Ph.D. Director, Neuroscience Drug Discovery and Development, UHN On behalf of the TDRA: Baycrest St. Michael s Hospital University
More informationONLY AT NYSCF Stem Cells in the City Sponsorship Offering
ONLY AT NYSCF The New York Stem Cell Foundation (NYSCF) accelerates cures and better treatments for patients through stem cell research. The NYSCF global community includes over 140 researchers at leading
More informationMASSACHUSETTS ALZHEIMER S DISEASE RESEARCH CENTER
MASSACHUSETTS ALZHEIMER S THE NEWSLETTER DISEASE RESEARCH OF THE CENTER Volume 1, Issue 4 Winter 2010 http://madrc.mgh.harvard.edu/ Mild Cognitive Impairment (MCI) A new look at early changes MASSACHUSETTS
More informationParkinson s Research Program
Parkinson s Research Program Strategic Plan INTRODUCTION The Congressionally Directed Medical Research Programs (CDMRP) represents a unique partnership among the U.S. Congress, the military, and the public
More informationPeer Reviewed Alzheimer s Research Program (PRARP)
Peer Reviewed Alzheimer s Research Program (PRARP) Col Wanda L. Salzer, USAF Director, CDMRP Anthony Pacifico, Ph.D. Program Manager, PRARP Disclaimer The information in this presentation is the opinion
More informationMeeting California s Cancer Challenges. UC Cancer Consortium
Meeting California s Cancer Challenges UC Cancer Consortium 2017 Despite steady declines in cancer rates over the past 20 years, cancer is soon expected to overtake heart disease as California s leading
More informationFOR IMMEDIATE RELEASE July 26, 2018 Eisai Co., Ltd. Biogen Inc.
FOR IMMEDIATE RELEASE July 26, 2018 Eisai Co., Ltd. Biogen Inc. EISAI AND BIOGEN ANNOUNCE DETAILED RESULTS OF PHASE II CLINICAL STUDY OF BAN2401 IN EARLY ALZHEIMER S DISEASE AT ALZHEIMER S ASSOCIATION
More informationUC San Diego HIV Institute Creating a Future Without HIV/AIDS
UC San Diego HIV Institute Creating a Future Without HIV/AIDS Executive Summary HIV/AIDS will never cure itself, but at the University of California San Diego and UC San Diego Health, we believe that we
More informationDEMENTIA: IMPLEMENTATION REPORT AND CURRENT DEVELOPMENTS EU HEALTH
DEMENTIA: IMPLEMENTATION REPORT AND CURRENT DEVELOPMENTS EU HEALTH Brussels, 19 March 2015 Michael Hübel Programme Management and Diseases Directorate-General for Health and Food Safety European Commission
More informationNIH Alzheimer s Disease Centers Panel Recommendations
NIH Alzheimer s Disease Centers Panel Recommendations In June, 2017 NIA engaged leading experts from academia, industry and non-profit foundations, working in Alzheimer s and other complex diseases, in
More informationPROJECT TRICALS AN INTERNATIONAL COLLABORATION TO FIND EFFECTIVE TREATMENTS FOR AMYOTROPHIC LATERAL SCLEROSIS
PROJECT TRICALS AN INTERNATIONAL COLLABORATION TO FIND EFFECTIVE TREATMENTS FOR AMYOTROPHIC LATERAL SCLEROSIS BACKGROUND Amyotrophic Lateral Sclerosis (ALS), also known as Motor Neurone Disease (MND) is
More informationCSF Aβ1-42 predicts cognitive impairment in de novo PD patients
CSF Aβ1-42 predicts cognitive impairment in de novo PD patients Mark Terrelonge MPH *1, Karen Marder MD MPH 1, Daniel Weintraub MD 2, Roy Alcalay MD MS 1 1 Columbia University Department of Neurology 2
More informationEngineering team: Andrew Lang, Bo Liu, Jerry Prince, Brian Caffo, Murat bilgel, Runze Tan, Chun-Guang, and Zhou Ye; Medical team: Kostas Lyketsos,
Engineering team: Andrew Lang, Bo Liu, Jerry Prince, Brian Caffo, Murat bilgel, Runze Tan, Chun-Guang, and Zhou Ye; Medical team: Kostas Lyketsos, Susan Resnik, Sterling Johnson, and Pierre Jedynak Longitudinal
More informationThe West Point Senior Care Study UPDATE 18 MAY 11
The West Point Senior Care Study UPDATE 18 MAY 11 Introduction Paula A Corrigan, MD MPH Col USAF MC CFS Program Director General Preventive Medicine Residency USAFSAM, Brooks City-Base TX Principle Investigator
More informationImproving diagnosis of Alzheimer s disease and lewy body dementia. Brain TLC October 2018
Improving diagnosis of Alzheimer s disease and lewy body dementia Brain TLC October 2018 Plan for this discussion: Introduction to AD and LBD Why do we need to improve diagnosis? What progress has been
More informationNIH FY 2017 Budget Roll-Out Francis S. Collins, M.D., Ph.D. Director, National Institutes of Health February 9, 2016
NIH FY 2017 Budget Roll-Out Francis S. Collins, M.D., Ph.D. Director, National Institutes of Health February 9, 2016 NIH s FY 2017 Budget Request Year FY 2015 FY 2016 FY 2017 Request Program Level ($B)
More informationCreating new models for R&D in areas of unmet medical need: Autism Spectrum Disorders
Creating new models for R&D in areas of unmet medical need: Autism Spectrum Disorders Will Spooren F. Hoffmann-La Roche Autism spectrum disorders (ASD): Current situation Anti-convulsants Sleep-medication
More informationOpportunities in Pain Research with the NIH HEAL Initiative
Opportunities in Pain Research with the NIH HEAL Initiative Clinton Wright, M.D. Director, Division of Clinical Research National Institute of Neurological Disorders and Stroke, NIH September 20, 2018
More informationMild Cognitive Impairment (MCI)
October 19, 2018 Mild Cognitive Impairment (MCI) Yonas E. Geda, MD, MSc Professor of Neurology and Psychiatry Consultant, Departments of Psychiatry & Psychology, and Neurology Mayo Clinic College of Medicine
More informationDr. Michael Lobatz Dr. Michael Jackson Dr. James Brewer Dr. Paul Aisen. Dr. Michael Plopper. Dr. Guerry Peavy
1 Anne State 2 3 Dr. Michael Lobatz Dr. Michael Jackson Dr. James Brewer Dr. Paul Aisen Dr. Michael Plopper Dr. Guerry Peavy 4 Michael Lobatz, MD Medical Director, Neurosciences Medical Director, Rehabilitation
More informationTranslating Duke Health. Accelerating discovery and its translation
Translating Duke Health Accelerating discovery and its translation Translating Duke Health Biomedical discovery is accelerating innovative and revolutionary advancements in our understanding of human biology,
More informationAlzheimer s Disease Genetics Consortium ADGC. Alzheimer s Disease Sequencing Project ADSP
Alzheimer s Disease Genetics Consortium ADGC Alzheimer s Disease Sequencing Project ADSP National Institute on Aging Genetics of Alzheimer s Disease Storage site NIAGADS Partners: National Alzheimer Coordinating
More informationNeurology & Brain Disorders
International Congress on Neurology & Brain Disorders 16-18 September, 2019 London, UK "Accelerate the latest innovations and developing trends on Neurology and Brain Disorders" About Conference Science
More informationALZHEIMER'S DISEASE PREVENTION TRIALS
ALZHEIMER'S DISEASE PREVENTION TRIALS Laurie Ryan, PhD Chief, Dementias of Aging Branch & Program Director, Alzheimer s Disease Clinical Trials Division of Neuroscience National Institute on Aging/National
More informationEuropean Prevention of Alzheimer s Dementia (EPAD)
European Prevention of Alzheimer s Dementia (EPAD) Ron Marcus, MD ISCTM Adaptive Design Workshop February 20, 2018 1 EPAD Goal The European Prevention of Alzheimer's Dementia (EPAD) project aims to develop
More informationAlzheimer s Disease Information Network ADIN Monthly E-News. Scientists Find New Link Between Diabetes and Alzheimer s. For more information
Alzheimer s Disease Information Network ADIN Monthly E-News Alzheimer s Disease Cooperative Study June 2015 For more information on clinical trials, visit the NIA s Redesigned ADEAR Clinical Trials Website
More informationENDING FAMILY HOMELESSNESS IN THE SAN FRANCISCO UNIFIED SCHOOL DISTRICT. Case Statement
ENDING FAMILY HOMELESSNESS IN THE SAN FRANCISCO UNIFIED SCHOOL DISTRICT Case Statement Overview There are more than 1,800 homeless students in San Francisco s public schools translating to approximately
More informationAlzheimer s Biomarkers Consortium of Down Syndrome (ABC-DS)
Alzheimer s Biomarkers Consortium of Down Syndrome (ABC-DS) AN OVERVIEW (with material provided by Ben Handen & Nicole Schupf) https://www.nia.nih.gov/research/abc-ds Alzheimer s Biomarkers Consortium
More informationCan aspirin slow cognitive decline and the onset of dementia? The ASPREE study. Mark Nelson on behalf of ASPREE Investigators
Can aspirin slow cognitive decline and the onset of dementia? The ASPREE study. Mark Nelson on behalf of ASPREE Investigators ASPREE Randomized, double-blind, placebo-controlled trial for extending healthy
More informationREPORT TO CONGRESS Multi-Disciplinary Brain Research and Data Sharing Efforts September 2013 The estimated cost of report or study for the Department of Defense is approximately $2,540 for the 2013 Fiscal
More informationThe Gary and Mary West Senior Dental Center: An Integrated Model of Dental, Health, and Wellness Care for Older Adults
The Gary and Mary West Senior Dental Center: An Integrated Model of Dental, Health, and Wellness Care for Older Adults National Network for Oral Health Access Monday, November 13, 2017 Thank you for joining
More informationAchieva 7.0T put into action in Alzheimer s disease research
Publication for the Philips MRI Community Issue 43 MaY 2011 Achieva 7.0T put into action in Alzheimer s disease research With its exceptionally high SNR, 7.0T MR is used in research on Alzheimer s disease
More informationHHS Public Access Author manuscript Alzheimers Dement. Author manuscript; available in PMC 2016 July 01.
Impact of the Alzheimer s Disease Neuroimaging Initiative, 2004 to 2014 Michael W. Weiner a,b,c,d,e,*, Dallas P. Veitch a, Paul S. Aisen f, Laurel A. Beckett g, Nigel J. Cairns h,i, Jesse Cedarbaum j,
More informationWorkgroup on NAPA s scientific agenda for a national initiative on Alzheimer s disease
Alzheimer s & Dementia 8 (2012) 357 371 Policy Forum Workgroup on NAPA s scientific agenda for a national initiative on Alzheimer s disease Alzheimer s Association Expert Advisory Workgroup on NAPA*,y
More informationBigomics : Challenges and promises in large scale sequencing projects
Bigomics : Challenges and promises in large scale sequencing projects Theodore M. Wong Ken Yocum MSST 2014 2010 Illumina, Inc. All rights reserved. Illumina, illuminadx, Solexa, Making Sense Out of Life,
More informationFROM THE ALZHEIMER S ASSOCIATION INTERNATIONAL CONFERENCE 2017 NEW AND EXPANDED RISK FACTORS FOR COGNITIVE DECLINE AND ALZHEIMER S DISEASE
CONTACT: Alzheimer s Association International Conf. Press Office, +44 (0) 20-7069-6000, media@alz.org Niles Frantz, Alzheimer s Association, + 1 312-363-8782, nfrantz@alz.org FROM THE ALZHEIMER S ASSOCIATION
More informationPeer Reviewed Alzheimer s Research Program
Peer Reviewed Alzheimer s Research Program US Army Medical Research and Materiel Command Congressionally Directed Medical Research Programs HISTORY The Congressionally Directed Medical Research Programs
More informationBoston Scientific is advancing...
Boston Scientific is advancing... Our mission Our values Boston Scientific is dedicated to transforming lives through innovative Caring Meaningful Innovation High Performance medical solutions that improve
More informationJOSLIN INGENUITY DIGITAL IMPACT INNOVATION BIG DATA CAPACITY TRANSLATIONAL AGILITY COLLABORATION COLLABORATION JENESIS
CONFIDENCE OUTCOMES ALLIANCES CATALYST COLLABORATION AGILITY JOSLIN INGENUITY CAPACITY IMPACT INNOVATION GLOBAL ACCELERATION COLLABORATION JENESIS BIG DATA TRANSLATIONAL DIGITAL Contents 2 Partnering for
More informationUNIVERSITY OF CALIFORNIA, SAN FRANCISCO CONSENT TO PARTICIPATE IN A RESEARCH STUDY
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO CONSENT TO PARTICIPATE IN A RESEARCH STUDY Epileptic Encephalopathies: Clinical and Genetic Predictors of Outcomes and Therapeutic Insights This is a research study.
More informationFinnGen as a Honey Jar for Additional Biomedical studies. Eero Punkka, Helsinki Biobank
1 FinnGen as a Honey Jar for Additional Biomedical studies 2 Eero Punkka, Helsinki Biobank FinnGen Step 1: Producing genome data 1O % of the population Step 2: Combining genome data with digital health
More informationAVENIO ctdna Analysis Kits The complete NGS liquid biopsy solution EMPOWER YOUR LAB
Analysis Kits The complete NGS liquid biopsy solution EMPOWER YOUR LAB Analysis Kits Next-generation performance in liquid biopsies 2 Accelerating clinical research From liquid biopsy to next-generation
More informationNAVIFY Tumor Board NAVIFY
NAVIFY Tumor Board Make the most informed personalized treatment decisions possible by leveraging innovative technologies and the latest scientific and clinical data WHAT S INSIDE Key Takeaways NAVIFY
More informationWelcome to today s webinar
Welcome to today s webinar We will begin the webinar at 2:00 p.m. Eastern All attendee lines are automatically muted. This webinar is being recorded and will be posted on LBDA s Youtube page. Throughout
More informationAustralasian Sleep Association
Australasian Sleep Association Submission to The Government s Review Panel Mr Simon McKeon, Prof. Henry Brodaty AO, Prof. Ian Frazer, Prof. Melissa Little, Ms Elizabeth Alexander AM and Mr Bill Ferris
More information2018 INFUSE CALL FOR INNOVATION
2018 INFUSE CALL FOR INNOVATION Leveraging digital technologies for registration, identification, digital record-keeping and follow-up to ensure healthier futures Imagine a future in which all children
More informationDefeat Dementia. Five years and 100m of investment to power transformational patient benefit
Defeat Dementia Five years and 100m of investment to power transformational patient benefit An ambition to solve our greatest medical challenge Dementia is our greatest medical challenge. There is currently
More informationSource: National Geographic.
Source: National Geographic. Living to 1,000: Impossible or Within Reach? Lorelei Mucci, ScD, MPH, Associate Professor of Epidemiology, Harvard School of Public Health Source: Harvard. Living to 1,000:
More informationParkinson s Research and the New Centre for Brain Health at UBC. Case for Support The University of British Columbia Faculty of Medicine
Parkinson s Research and the New Centre for Brain Health at UBC Case for Support The University of British Columbia Faculty of Medicine THE VALUE OF A HEALTHY BRAIN By 2020, brain disease will overtake
More informationMemory Research Suite
Memory Research Suite http://alz.health.usf.edu (813) 396-0606...until Alzheimer s is a memory On The Road to Curing Alzheimer s The Quest for Answers The next big breakthroughs in treating Alzheimer s
More informationInvolving research participants in research: The example of the EPAD (European Prevention of Alzheimer s Dementia) project
Involving research participants in research: The example of the EPAD (European Prevention of Alzheimer s Dementia) project Stina Saunders Alzheimer Europe Annual Conference Barcelona 2018 @stina_saunders
More informationEXPERT CONSULTATION ON UNLOCKING GLOBAL COLLABORATION TO ACCELERATE INNOVATION FOR ALZHEIMER S DISEASE AND DEMENTIA.
EXPERT CONSULTATION ON UNLOCKING GLOBAL COLLABORATION TO ACCELERATE INNOVATION FOR ALZHEIMER S DISEASE AND DEMENTIA 20-21 June, 2013 The Harris Manchester College Oxford, United Kingdom Background The
More informationAnonymous responses from organisations ID code Country Page 1944 France 18
Funding agency, policy-maker & regulator respondees Responses from organisations ID code Organisation Country Page 1627 European Alliance for Restless Legs Syndrome Netherlands 2 1727 Royal Dutch Society
More informationDiversity, Health Disparities and Population Health
Diversity, Health Disparities and Population Health UAHS Discovery Lunch December 18, 2015 Joe G.N. Skip Garcia, MD Senior Vice President for Health Sciences Dr. Merlin DuVal Professor of Medicine 1 Five
More informationThe 90+ Study Studies of The Oldest-Old
The National Cell Repository for Alzheimer s Disease (NCRAD) is a data and specimen collection source for families with Alzheimer s disease (AD) or serious memory loss. Families having two or more living
More informationAngelman Syndrome Roadmap to a Cure
The Need: Angelman Syndrome Roadmap to a Cure The Foundation for Angelman Syndrome Therapeutics (FAST) is focused on funding research that will lead to a cure for Angelman Syndrome (AS). There are almost
More informationIdentification & Diagnosis of Cryptogenic Stroke What is NINDS/role
Identification & Diagnosis of Cryptogenic Stroke What is NINDS/role October 9, 2015 Scott Janis, Ph.D. Program Director, National Institute of Neurological Disorders and Stroke, The National Institute
More informationMolecular Imaging and the Brain
Molecular imaging technologies are playing an important role in neuroimaging, a branch of medical imaging, by providing a window into the living brain. Where CT and conventional MR imaging provide important
More informationThe Neighborhood Atlas:
The Neighborhood Atlas: Local Health and Social Disadvantage October 19, 2018 Amy Kind, MD, PhD Director, Department of Medicine Health Services and Care Research Program Associate Professor, Department
More informationImplementation of fully automated immunoassays for CSF Aβ 1-42, t-tau and p-tau 181 in the Alzheimer s Disease Neuroimaging Initiative
Implementation of fully automated immunoassays for CSF Aβ 1-42, t-tau and p-tau 181 in the Alzheimer s Disease Neuroimaging Initiative Leslie M Shaw Perelman School of Medicine, University of Pennsylvania
More information2015 SPONSORSHIP PACKET. Alzheimer s Association South Texas Chapter. Natasha Sobers
2015 SPONSORSHIP PACKET Alzheimer s Association South Texas Chapter Natasha Sobers 210.710.5153 nsobers@alz.org INTRODUCTION About the Alzheimer s Association The Alzheimer's Association is the world s
More informationUSE OF BIOMARKERS TO DISTINGUISH SUBTYPES OF DEMENTIA. SGEC Webinar Handouts 1/18/2013
Please visit our website for more information http://sgec.stanford.edu/ SGEC Webinar Handouts 1/18/2013 2013 WEBINAR SERIES STATE OF THE SCIENCE: DEMENTIA EVALUATION AND MANAGEMENT AMONG DIVERSE OLDER
More informationMentis Cura November
Mentis Cura November 29 2012 www.mentiscura.com New Facts on Alzheimer s Death rank nr. 2-5 in western countries Fastest growing disease in: Cost Incedence Death rate People with Alzheimer s 2012 36 million
More information$884,000 to Melanoma Research
$884,000 to Melanoma Research EVERY DOLLAR IN GOES OUT! The Miller family funds all event and foundation costs so that every dollar raised goes directly to research and is 100% tax deductible. $734,000
More informationOn behalf of the Infectious Diseases Society of America (IDSA), I offer testimony in
Testimony of the Infectious Diseases Society of America (IDSA) on the Fiscal Year 2018 Department of Health and Human Services Budget Prepared for the U.S. House of Representatives Subcommittee on Labor-HHS-Education
More informationAVENIO family of NGS oncology assays ctdna and Tumor Tissue Analysis Kits
AVENIO family of NGS oncology assays ctdna and Tumor Tissue Analysis Kits Accelerating clinical research Next-generation sequencing (NGS) has the ability to interrogate many different genes and detect
More informationFROM THE ALZHEIMER S ASSOCIATION INTERNATIONAL CONFERENCE 2018
FOR IMMEDIATE RELEASE CONTACT: Alzheimer s Association AAIC Press Office, 312-949-8710, aaicmedia@alz.org Niles Frantz, Alzheimer s Association, 312-335-5777, nfrantz@alz.org FROM THE ALZHEIMER S ASSOCIATION
More informationAn Extraordinary Resource for Cancer Care
An Extraordinary Resource for Cancer Care Anderson Family Cancer Institute The Campaign for Jupiter Medical Center Gaining Critical Mass Against Cancer $50 Million fundraising goal to build our new cancer
More informationRestoration. JDRF is turning Type One into Type None. attack so the newly restored beta cell function is protected.
Restoration JDRF is turning Type One into Type None Type 1 diabetes (T1D) is an extraordinarily complex disease. Finding the cure a short-term clinical intervention, with minimal side effects, after which
More informationAlzheimer s disease public-private partnerships: Update 2017
Alzheimer s & Dementia - (2018) 1-10 Research News Alzheimer s disease public-private partnerships: Update 2017 Heather M. Snyder a, *, William R. Perlman b, Robert Egge c, Maria C. Carrillo a a Medical
More informationCarotid Artery Reactivity Measurement among Healthy Young People towards Early Detection of Alzheimer Disease
Carotid Artery Reactivity Measurement among Healthy Young People towards Early Detection of Alzheimer Disease MOHD AMINUDIN JAMLOS, EKO SUPRIYANTO Department of Clinical Science and Engineering Faculty
More informationFinding Solutions to the Alzheimer s Disease Epidemic in Indiana: Alzheimer s Research in Indiana
Finding Solutions to the Alzheimer s Disease Epidemic in Indiana: Alzheimer s Research in Indiana Bruce Lamb, Ph.D. Executive Director Stark Neurosciences Research Institute September 13, 2017 Critical
More informationdrug discovery 8 9, 36, 42, 70, 73, , , 169, 172, , , 231, drug-induced liver injury (DILI) 93
Index ADNI see Alzheimer s Disease Neuroimaging Initiative adoption, clinical 90, 92 age-related macular degeneration (AMD) 148 49, 159, 161 AIDS vaccine 242, 250 51, 253 AIDS vaccine research 248 49,
More informationTransforming Data into Actionable Knowledge
Transforming Data into Actionable Knowledge AIPHD Dental Informatics Colloquium, San Antonio TX January 20, 2017 Transforming Big and SMALL Data in Oral Health It is not about the Data Oral Health Priority
More informationCYGNUS: A digital brain health platform for improving dementia outcomes
CYGNUS: A digital brain health platform for improving dementia outcomes Léa Marais - IXICO Hakim Yadi - Northern Health Science Alliance www.ecygnus.com Background to Cygnus Many people with dementia are
More informationAn integrated natural disease progression model of nine cognitive and biomarker endpoints in patients with Alzheimer s Disease
An integrated natural disease progression model of nine cognitive and biomarker endpoints in patients with Alzheimer s Disease Angelica Quartino 1* Dan Polhamus 2*, James Rogers 2, Jin Jin 1 212, Genentech
More information